🧠 Braelyn is 18 years old and fighting
#glioblastoma.
#NWBO #DCVax #EmoryProton #UCLA #GBM #ProtonTherapy #BraelynStrong
Her family has built a science-driven treatment plan and they are executing it in real time against real setbacks.
📄 I published a detailed scientific analysis tracing why proton radiation and dendritic cell vaccination are not two separate treatments but a single integrated architecture:
x.com/andrewcaravello/status…
"The Dual Dividend" assembles 74 peer-reviewed sources across Nature, Immunity, The Lancet, JAMA Oncology, and the Journal of Clinical Investigation. Here is what it shows:
⚡ THE DUAL DIVIDEND
Proton radiation delivers two simultaneous benefits. It preserves the immune substrate the vaccine needs: monocytes, CD4 T cells, NK cells, TCR diversity, lymph node architecture. And it conditions the tumor for immune recognition: calreticulin exposure, MHC-I upregulation, 30 consecutive days of cGAS-STING activation, blood-brain barrier opening, and chemokine reprogramming.
Photon radiation generates the same tumor signals then destroys the immune cells that would respond. The signal without the receiver is noise.
📊 KEY EVIDENCE
Frank Phase III (Lancet 2026): first randomized survival proof for protons in any cancer. 5-year OS 90.9% vs 81.0% (HR 0.58, P = 0.045)
Mohan Phase II in GBM: G3 lymphopenia 14% proton vs 39% photon. Female sex = strongest predictor (OR 6.2, P = 0.003)
Coupey 2026: proton radiation caused zero myeloid depletion. Photons halved the myeloid compartment in 12 hours. Monocytes are what the vaccine is made from
Lei CRISPR proof: the licensing circuit requires CD40L AND IFNβ simultaneously. Photon-depleted CD4 = circuit FALSE at first node
DCVax-L Phase III: 331 patients, mOS 19.3 vs 16.5 mo (HR 0.80, P = 0.002). The only DC vaccine with Phase III survival evidence in GBM
🔬 THE LICENSING CIRCUIT
The analysis maps a Boolean dependency at the center of vaccine efficacy: CD4 T cells must deliver two signals simultaneously to license cDC1 dendritic cells for cross-presentation. If CD4 cells are depleted by photon radiation, the entire downstream cascade (IL-12p70 production, CD8 T cell priming, epitope spreading) cannot initiate. The vaccine arrives but no one can receive the instruction. Proton radiation keeps that gate open.
🔄 THE REFRAME
Most oncologists still view proton therapy as simply "less toxic radiation." Many families are told it is unnecessary or equivalent to standard photon treatment. Braelyn's family knew better and sought proton therapy from the start. When the proton center in Charlotte declined her case because of its complexity, it felt like a setback. It was not. Dr. Michels personally called Emory, one of the most advanced proton centers in the country, and they agreed to treat her. The science shows that for a patient who will receive a dendritic cell vaccine, proton radiation is not a luxury or a preference. It is a mechanistic prerequisite. It preserves the very cells the vaccine is manufactured from and the very cells the vaccine must teach. What looked like a closed door led directly to a better one.
🧬 WHY BRAELYN
Her situation maps directly onto this architecture:
MGMT-unmethylated: temozolomide offers less benefit. Her immune system is the primary therapeutic mechanism
Female: the Mohan trial specifically indicates proton therapy for women (OR 6.2)
Age 18: still has active thymic function, faster immune reconstitution, and broader T cell diversity than older patients. These are advantages proton radiation preserves and photons would erode
🏥 THIS WEEK
Her local oncologist Dr. Michels personally called
#Emory to secure proton radiation after Charlotte declined. Her family completed their first telehealth with Dr. Ashkan in the UK to plan the autologous dendritic cell vaccine (ADCV), the same platform tested in the
#DCVax Phase III trial, through compassionate use. Dr. Liau at
#UCLA is coordinating directly and is emerging as a key figure in Braelyn's care.
🗓️ THE PATH
Proton radiation at Emory → recovery window with steroid taper → leukapheresis to collect immune cells → ADCV manufactured from her own blood → vaccination series beginning in the UK in early June
Every step has a defined biological purpose. Every decision connects to the next.
💛 THE ASK
But the costs are real. Six weeks of daily proton treatment in Atlanta. International travel to the UK. Compassionate use coordination. Medical expenses no insurance fully covers. All for a young woman whose life is just beginning.
This family is not waiting for someone to save them. They have been building this from day one, seeking out every treatment, coordinating across three countries, assembling a team of physicians who believe in this approach. They just need help getting there.
To the
#NWBO and
#DCVax community, to every shareholder, every patient family, every person who understands what this platform means: Braelyn's treatment plan is built on the science you have supported. This is what it looks like when the science reaches a patient.
Please share this post. Please help if you are able.
🧡
givesendgo.com/GB5RT
#DCVax #NWBO #Glioblastoma #ProtonTherapy #EmoryProton #UCLA #WinshipCancer #DendriticCell #Immunotherapy #ADCV #BraelynStrong
Follow Braelyn’s journey and support her family:
@HollensbeAmanda